ECC 2015 Recap: RCC Recommendations From Dr. Bradley Somer
Dr. Bradley Somer, member of the Editorial Board of PracticeUpdate RCC, recommends the following abstracts which were presented at the European Cancer Congress 2015 held in Vienna, Austria, from September 25 to 29, 2015.
Saturday, September 26, 2015
2:30 PM–4:30 PM Presidential Session I
Abstract 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). Presented by P Sharma
Take-home message
- In this phase III study, 821 patients with clear cell advanced or metastatic renal cell carcinoma were randomized to treatment with nivolumab or everolimus. Median overall survival was 25 months with nivolumab compared with 19.6 months with everolimus. The most common adverse events were fatigue (both treatments), nausea and pruritus (nivolumab), and stomatitis and anemia (everolimus).
- Nivolumab improved survival and was associated with fewer adverse events compared with everolimus in patients with advanced renal cell carcinoma.
Abstract 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial. Presented by T Choueiri
Take-home message
- In this phase III trial, researchers randomized 658 patients with clear cell renal cell carcinoma to receive cabozantinib or everolimus. Median progression-free survival was 7.4 months with cabozantinib compared with 3.8 months with everolimus. Overall survival was not determined. Cabozantinib was associated with abdominal pain (3%), pleural effusion (2.7%), and diarrhea (2.1%). Everolimus was associated with anemia (3.7%), dyspnea (3.7%), and pneumonia (3.7%).
- Cabozantinib improved progression-free survival and objective response rate compared with everolimus in patients with advanced clear cell renal cell carcinoma.
Sunday, September 27, 2015
9:15 AM–10:25 AM Proffered Paper Session: Immunotherapy in Cancer I
Abstract 17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC. Presented by B Rini
Take-home message
- In this phase III study, researchers randomized patients with HLA-A*02–positive metastatic renal cell carcinoma already taking sunitinib to also receive or not receive IMA901 cancer vaccine. Overall survival was not different between the groups, and both groups had similar rates of adverse events.
- The researchers concluded that further research is needed to improve the magnitude of immune responses with IMA901 cancer vaccine.
Abstract 2509 Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma. Presented by T Hudson
Take-home message
- Researchers randomized 288 treatment-naïve patients with clear cell metastatic renal cell carcinoma to receive axitinib or sorafenib. Median overall survival was not statistically different between the groups. Median overall survival was 41.2 months and 14.2 months in patients receiving axitinib and ECOG performance status 0 and 1, respectively. In the patients taking sorafenib, median overall survival was 31.9 months and 19.8 months for ECOG performance status 0 and 1, respectively.
- Overall survival was similar between axitinib and sorafenib. The researchers suggest that practice standards in resource-limited geographic regions may have impacted the overall survival differences with axitinib.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles:
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.